← Leaderboards
Sasantha Jeson Sangaralingham
Mayo Clinic Rochester
$3,919,348
Attributed
$6,759,532
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,759,532 · 3
By mechanism
R01$6,759,532 · 3
Top collaborators
- Siobhan Malany7 shared
- John C Burnett4 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Horng H Chen$12,297,202
- Siobhan Malany$5,060,787
- Thomas Patrick Olson$5,622,167
- Alessandro Cataliotti$966,441
- Yasuhiro Ikeda$1,841,468
Others in their field
Top investigators on “Cyclic Gmp”
- Leonard Freedman · Leidos Biomedical Research, Inc.$239,520,687
- David Heimbrook · Leidos Biomedical Research, Inc.$138,433,241
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,746,909
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Putta Neeraja · Fisher Bioservices, Inc.$28,277,912
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$28,173,207
Research focus
Cyclic GmpCardiacLeadSecond Messenger SystemsBiologyNovel TherapeuticsPathway InteractionsPeptidesHeart FailurePharmaceutical PreparationsParticulateDrug DiscoveryCardiovascular DiseasesMediatingHeartIn VitroFibrosisGenerationsBiologicalKidneyEngineeringIn VivoDesignBiological Availability
Grant awards (12)
Novel Therapeutics for Cardiovascular Disease$681,486
R01 · FY2025 · HL · contact PI
Novel Therapeutics for Cardiovascular Disease$672,130
R01 · FY2024 · HL · contact PI
Novel Therapeutics for Cardiovascular Disease$693,407
R01 · FY2023 · HL · contact PI
Novel Therapeutics for Cardiovascular Disease$715,647
R01 · FY2022 · HL · contact PI
Cardiorenal Fibrosis: Biology and Therapeutics$397,500
R01 · FY2020 · HL · contact PI
Small Molecule Discovery for Particulate Guanylyl Cyclase Receptor B Enhancers$651,411
R01 · FY2019 · AG · contact PI
Cardiorenal Fibrosis: Biology and Therapeutics$397,500
R01 · FY2019 · HL · contact PI
Small Molecule Discovery for Particulate Guanylyl Cyclase Receptor B Enhancers$712,741
R01 · FY2018 · AG · contact PI
Cardiorenal Fibrosis: Biology and Therapeutics$397,500
R01 · FY2018 · HL · contact PI
Small Molecule Discovery for Particulate Guanylyl Cyclase Receptor B Enhancers$645,210
R01 · FY2017 · AG · contact PI
Cardiorenal Fibrosis: Biology and Therapeutics$397,500
R01 · FY2017 · HL · contact PI
Cardiorenal Fibrosis: Biology and Therapeutics$397,500
R01 · FY2016 · HL · contact PI